RTP Mobile Logo
Select Publications

Abou-Alfa GK et al. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. ASCO 2018;Abstract TPS4144.

Bruix J et al. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016;150(4):835-53. Abstract

Chen Y et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 2015;61(5):1591-602. Abstract

Finn RS et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New Engl J Med 2020;382(20):1894-905. Abstract

Finn RS et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial. J Clin Oncol 2020;38(3):193-202. Abstract

Greten TF et al. Immunotherapy of HCC. Rev Recent Clin Trials 2008;3(1):31-9. Abstract

Hedge PS et al. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol 2018;52(Pt 2):117-24. Abstract

Kelley RK et al. Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. ASCO 2019;Abstract TPS4157.

Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90. Abstract

Minchot JM et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer 2016;54:139-48. Abstract

Yau T et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. ASCO 2019;Abstract 4012.

Zhu AX et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19(7):940-52. Abstract